GGF2 is a recombinant human neuregulin-1b in development for chronic heart failure. Phase 1 clinical trials of GGF2 were put on hold when transient elevations in serum aminotransferases and total bilirubin were observed in 2 of 43 subjects who received single doses of GGF2 at 1.5 or 0.378 mg/kg. However, aminotransferase elevations were modest and not typical of liver injury sufficient to result in elevated serum bilirubin. Cynomolgus monkeys administered a single 15 mg/kg dose of GGF2 had similar transient elevations in serum aminotransferases and bilirubin as well as transient elevations in serum bile acids. However, no hepatocellular necrosis was observed in liver biopsies obtained during peak elevations. When sandwich-cultured human hepatocytes were treated with GGF2 for up to 72 h at concentrations approximately 0.8-fold average plasma C max for the 0.378 mg/kg dose, no cytotoxicity was observed. Gene expression profiling identified approximately 50% reductions in mRNAs coding for bilirubin transporters and bile acid conjugating enzymes, as well as changes in expression of additional genes mimicking the interleukin-6-mediated acute phase response. Similar gene expression changes were observed in GGF2-treated HepG2 cells and primary monkey hepatocytes. Additional studies conducted in sandwich-cultured human hepatocytes revealed a transient and GGF2 concentration-dependent decrease in hepatocyte bile acid content and biliary clearance of taurocholate without affecting biliary taurocholate efflux. Taken together, these data suggest that GGF2 does not cause significant hepatocellular death, but transiently modifies hepatic handling of bilirubin and bile acids, effects that may account for the elevations in serum bilirubin observed in the clinical trial subjects.
Isoforms of neuregulin-1 (NRG-1) comprise a well-studied family of trophic factors known to play roles in nervous system and cardiac tissue morphogenesis as well as in homeostatic maintenance of cellular viability and metabolism in a broad array of adult tissues (Falls et al., 1993; Goodearl et al., 1993; Holmes et al., 1992; Marchionni et al., 1993; Peles et al., 1992; Wen et al., 1992) . NRG-1 ligand action is mediated by activation of ErbB receptor signaling. In the cardiac microvasculature, NRG-1/ErbB signaling is critical for adult cardiac health through paracrine mechanisms involving endothelial, endocardial, and cardiomyocyte interactions (Rupert and Coulombe, 2015; Sawyer and Caggiano, 2011) . Clinical development of the recombinant NRG-1 isoform, GGF2 (USAN-cimaglermin alfa), was initiated to evaluate its therapeutic potential for the treatment of chronic heart failure (Lenihan et al., 2016) . In phase 1 clinical trials, 2 of 43 subjects treated with a single dose of GGF2 at 1.5 or 0.378 mg/kg experienced clinical symptoms of liver injury (abdominal pain with flu-like symptoms) and concomitant elevations in serum aminotransferases and bilirubin, meeting the stopping criteria outlined in the FDA Guidance on drug-induced liver injury (DILI) (2009) . As a result, clinical development of GGF2 was temporarily placed on hold.
A complete description of the liver chemistry profile for the 2 aforementioned subjects is provided in Longo et al. (2017) . Changes in serum enzymes and bilirubin in these subjects normalized within approximately 1 week and peak alanine aminotransferase (ALT) elevations were relatively minor (<4xULN) compared with peak levels of direct bilirubin (>12xULN). These factors suggested that the liver abnormalities were not typical of the serum bilirubin elevations due to global liver dysfunction that have been defined as "Hy's Law" (Temple, 2006) . Moreover, DILIsym, a mechanistic, mathematical model of DILI, used serial measurement of serum ALT to estimate a maximum hepatocyte loss between 2% and 13% in these subjects, which would not be expected to cause sufficient liver dysfunction to result in a significant rise in serum bilirubin (Longo et al., 2017) This suggested that factors other than hepatocyte death underlie the rise in serum bilirubin in GGF2-treated subjects. In this study, several translational approaches were used to understand why GGF2 treatment would result in elevated serum bilirubin. A secondary objective was to account for the concomitant rise in serum ALT.
First, a single, high-dose of GGF2 was given to cynomolgus monkeys, which replicated, in part, the transient elevations in serum aminotransferases and bilirubin observed in the 2 subjects whose liver chemistry changes met the trial stopping criteria. This dosing regimen allowed for the sequential comparison of serum biomarkers with histologic changes until the injury resolved.
Next, gene expression profiling was performed in sandwichcultured human hepatocytes treated with GGF2. Prior cytochrome P450 (CYP) induction studies had unexpectedly demonstrated suppression of CYP3A4 mRNA in primary human hepatocytes exposed to GGF2 for 24 h. Although no direct cytotoxicity was observed in response to GGF2, the suppression of CYP3A4 transcript levels in primary hepatocyte cultures had a temporal profile consistent with the transient bilirubin elevations observed in vivo. Although downregulation of CYP3A4 alone should not influence serum bilirubin levels, it was reasoned that concomitant alterations in the expression of other liver proteins, such as those involved in bilirubin transport, could help to explain the liver response. The schematic in Figure 1A highlights the main hepatocyte proteins known to influence serum bilirubin levels (van de Steeg et al., 2012). Global gene expression profiling was used to interrogate the effect of GGF2 treatment on the expression of these genes as well as identify other factors that might explain the bilirubin response.
Finally, the effect of GGF2 on bile acid transport was also examined at the gene expression level using the microarray data and at the functional level using B-CLEAR technology in Transporter Certified human hepatocytes. Effects on bile acid transport were evaluated because its dysfunction could lead to alterations in bile acid homeostasis, subsequent bile acid accumulation, and hepatocyte death accounting for the modest elevations in serum ALT observed in the clinic and in the monkeys in response to GGF2 treatment (Woodhead et al., 2014; Woolbright et al., 2015) . Furthermore, elevations in serum bile acids were observed in the GGF2 treated monkeys. The schematic in Figure 1B highlights the main factors influencing the transport of bile acids in the liver (Roma et al., 2008) . These molecules were included in a targeted analysis of both the gene expression data and bile acid transport in GGF2-treated hepatocytes.
MATERIALS AND METHODS
Chemicals. GGF2 and GGF2 formulation buffer (vehicle; 20 mM Lhistidine, 100 mM sodium sulfate anhydrous, 100 mM L-arginine hydrochloride, 1% mannitol powder, pH 6.5) were provided by Acorda Therapeutics. Rifampin, cyclosporin A (CsA), and DMSO were purchased from Sigma, St. Louis, Missouri. Interleukin-6 (IL-6) was purchased from EMD-Millipore, Schematic of bilirubin transport shows the uptake of unconjugated bilirubin (UCB) into the liver through passive diffusion or an unknown transporter. UCB is conjugated by UGT1A1 and can then be transported into bile through MRP2 or BCRP1 or back out into blood through MRP3. UCB from blood is taken back up through OATP1B1/3. (B) Schematic of bile acid transport shows uptake of conjugated bile acids (CBA; bile salts) by NTCP. CBA can be transported into bile through MRP2 or BSEP or back out into blood through MRP3 or MRP4.
Endogenously synthesized bile acids (BA) can also be conjugated by BAAT and FATP5 and transported into bile or blood.
Burlington, Massachusetts. Deuterium-labeled chenodeoxycholic acid (d5-CDCA) was purchased from Toronto Research Chemicals, Ontario, Canada and taurocholic acid (d8-TCA) from Martrex, Inc, Chaska, Minnesota.
Nonclinical studies. All animal work was conducted at Biomere (Worcester, Massachusetts) in an AAALAC-International accredited facility and in accordance with the Guide for the Care and Use of Laboratory Animals (2011). Nine male cynomolgus monkeys (2.1-3.8 kg) were utilized in this study. During and following a quarantine period, monkeys were socially housed in appropriately sized cages and received standard primate chow (PMI Nutrition International Certified Primate Chow No. 5038, 25% protein) twice daily. Water was provided ad libitum. Environmental conditions were within recommended ranges for cynomolgus monkeys, and animals were maintained on 12-h light and dark cycles. On the day of GGF2 or vehicle treatment, the morning feeding was skipped prior to test article administration, but returned approximately 4 h thereafter. Monkeys were adapted to chair restraint prior to any experimentation. Animals were weighed 1 day prior to test article administration, 3 days after dosing, and 2 weeks after dosing and were observed daily over the course of the study for any health abnormalities.
Baseline blood samples collected 1 day prior to test article administration (day 0) and immediately before test article administration on day 1 were obtained for serum chemistry evaluation which included liver-related parameters and total bile acids (TBAs). Vehicle (N ¼ 1) or GGF2 at a dose of 15 mg/kg (N ¼ 8) was administered as a single intravenous bolus injection (1.5 ml/kg) to male cynomolgus monkeys (approximately 3 kg). Blood samples were collected for serum chemistry evaluation at 24 h postdose (day 2), as well as on days 3-7, 10, and 14. On days 4 and 14, liver biopsies were obtained surgically after blood samples were collected. Samples for the second biopsy were obtained from a liver site distant from the first biopsy. Biopsy specimens were drop-fixed in formalin, trimmed, paraffin embedded, serially sectioned and stained with hematoxylin-eosin, trichrome or Ki67. Standard clinical chemistry including a liver panel plus total serum bile acids was performed at IDEXX, Westbrook, Maine using a Beckman Coulter Chemistry System Model AU5400. Liver sections were then evaluated by a board-certified veterinary pathologist who also evaluated the serum chemistry results.
Cell culture for toxicogenomics. Culture and treatment of primary human hepatocytes were performed by QPS Hepatic Biosciences, Research Triangle Park, North Carolina. Hepatocytes obtained from Caucasian male donors (N ¼ 5, Supplementary Table 1) were used to replicate findings from previous in vitro studies and the race and sex of the 2 cases of elevated transaminases and bilirubin in the GGF2 clinical trials. Hepatocytes were cultured in a sandwich configuration using previously described methods (LeCluyse et al., 2005) . Treatment was initiated 24 h after seeding. Four treatment regimens were used for each donor including 3 different time points of continuous exposure (6, 24, and 72 h; media replaced every 24 h) plus a 24 h continuous exposure with a 48 h recovery (media changed to remove compound at 24 h; media replaced every 24 h). Hepatocytes were exposed to 5 different concentrations of GGF2 plus a GGF2 vehicle control (0.1% GGF2 formulation buffer), 1 concentration of rifampin (10 lM; positive control CYP3A4 inducer), 1 concentration of IL-6 (10 ng/ml; positive control CYP3A4 repressor), and a 0.1% DMSO control. Cell integrity was evaluated using phase contrast microscopy. Cytotoxicity was assessed by measuring lactate dehydrogenase (LDH) release into medium using the CytoTox-ONE Membrane Integrity Assay kit (Promega, Madison, Wisconsin) according to manufacturer's instructions.
Gene expression analysis for toxicogenomics. Cells were lysed using RLT buffer (Qiagen, Germantown, Maryland) mixed with Trizol (Life Technologies, Carlsbad, CA) at a 1: 1 ratio (200 ml total) and RNA isolated using either an RNeasy total RNA isolation kit or the QIAcube automated system (Qiagen) according to manufacturer's instructions. The quantity and integrity of the RNA was evaluated spectrophotometrically and with an Agilent 2100 Bioanalyzer. Isolated RNA from a single well of each positive control was used to assay for CYP3A4 gene expression. Total RNA from positive control wells (GGF2 vehicle control, 3760 pM GGF2, DMSO, rifampin, and IL-6) was reverse-transcribed according to the manufacturer's protocol using the High Capacity cDNA RT kit (Applied Biosystems, Foster City, CA). Resulting cDNA was amplified using the TaqMan Gene Expression master mix (Applied Biosystems) with FAM-MGB probes and primers for CYP3A4 as well as a housekeeping gene (GAPDH). After confirmation of CYP3A4 changes in response to positive control treatment, GGF2-treated wells from corresponding donors were used for microarray analysis. Doublestranded cDNA was synthesized from 50 to 150 ng (dependent on RNA yield) of total RNA, then transcribed to biotin-labeled cRNA using the 3 0 Express IVT kit (Affymetrix, Santa Clara, California) according to manufacturer's instructions. Labeled cRNA (15 lg) was fragmented and prepared for hybridization. The Affymetrix HT HG-U133 PM arrays were used with the Affymetrix Gene Titan system.
Statistical analysis for toxicogenomics. Statistical analyses for cytotoxicity and qPCR endpoints were performed using GraphPad Prism statistical software version 7.01. The fluorescence values from the individual secreted LDH samples were divided by the mean total LDH fluorescence value (sum of secreted and intracellular LDH) to determine the percent of LDH leakage (% total). The Ct values of CYP3A4 for each sample were normalized to the Ct values of the housekeeping gene and used to calculate a fold change (FC) over control with the 2 ÀDDCt method as previously described (Schmittgen and Livak, 2008) . Mean values of LDH (% total) and CYP3A4 (FC) for all donors were compared across treatment and time using a 2-way ANOVA. Comparisons between each treatment/concentration and the vehicle control within a time point were performed using either Bonferroni's or Dunnett's multiple comparison tests. Data for positive control and GGF2 were analyzed and reported independently. Gene expression analysis was performed in Partek Genomics Suite version 6.6 (Partek). Affymetrix CEL files were normalized using Robust Multi-array Average method with a log base 2 (log 2 ) transformation (Irizarry et al., 2003) . Two samples (Donor 4: 6 h: 0.376 pM GGF2 and Donor 5: 24 h: 0.1% GGF2 Buffer) failed QC and were omitted from analysis. Principal component analysis was used to evaluate the overall performance of the arrays and identify outliers. One group of samples, Donor 1: 6 h clustered together and were >3 SD away from the mean suggesting that these samples may also be aberrant and were therefore also omitted from analysis. A filtering step was performed to remove control probe sets, probe sets without mRNA annotation, and low expression probe sets. Gene expression differences were identified using ANOVA models with linear contrasts. Donor was identified as a significant factor contributing to the variability in probe intensity levels and was therefore used to normalize analyses where appropriate. Probability values were adjusted for multiple comparisons using a false discovery rate of 5% (FDR ¼ 0.05) (Benjamini and Hochberg, 1995) and an absolute value FC cutoff of >2 was also used as noted below. Pathways and toxicity lists enriched among statistically significant, differentially expressed genes in the data were identified using the Tox Analysis module in Ingenuity Pathway Analysis (Ingenuity Systems; Build version 389077M; Content version: 24718999). Gene expression data generated for this manuscript can be downloaded in its entirety from the Gene Expression Omnibus repository under the accession number GSE99926. All data are MIAME compliant.
Cell culture for evaluation of hepatobiliary disposition of bile acids. Culture and treatment of primary human hepatocytes were performed by Qualyst Transporter Solutions (QTS). Hepatocytes from human donors (N ¼ 3, Supplementary Table 2) were either purchased from Triangle Research Laboratories or Sekisui Xenotech and Transporter Certified by QTS prior to use in this study. Hepatocytes were cultured in a sandwich configuration per QTS standard operating procedures. Briefly, cryopreserved hepatocytes were seeded in QualGro Seeding Medium (QTS) at a density of 0.8-1.2 million viable cells/ml onto BioCoat (Corning) 24-well cell culture plates, and maintained under standard cell culture conditions (37 C, 5% CO 2 , 95% humidity). Following plating, cells were allowed to attach for 2-4 h, rinsed, and fed with warm (37 C) seeding medium. Eighteen to twenty-four hours later, cells were fed and overlaid with QualGro Hepatocyte Culture Induction Medium supplemented with 0.35 mg/ml Matrigel (Corning). Cells were maintained in QualGro Hepatocyte Culture Induction Medium for 5 days at which time the cells were consumed in sample analysis. Five treatment regimens were used for each donor including 4 different time points of continuous exposure (6, 24, 48, and 72 h; media replaced every 24 h) plus a 24 h continuous exposure with a 48 h recovery (media changed to remove compound at 24 h; media replaced every 24 h). Hepatocytes were exposed to 2 different concentrations of GGF2 plus a GGF2 vehicle control (0.1% GGF2 formulation buffer), 1 concentration of IL-6 (10 ng/ml; positive control CYP3A4 repressor), 1 concentration of d5-CDCA (100 mM; positive control suppressor of bile acid biosynthesis), 1 concentration of CsA (10 mM; positive control inhibitor of bile acid transport), and a 0.1% DMSO control.
Endogenous bile acid content and d8-TCA disposition evaluation. Endogenous bile acid content, endogenous bile acid and d8-TCA disposition were determined in sandwich-cultured human hepatocytes using B-CLEAR technology as previously described (Jackson et al., 2016) . Cell culture media was aspirated and frozen at -80 C until processed for endogenous bile acid bioanalysis. Cell culture plates were frozen at -80 C until processed for bioanalysis to determine protein content, composition and disposition of endogenous BA, and disposition of d8-TCA. Protein content was determined using Pierce BCA protein assay kit (Thermo Fisher Scientific) following manufacturer's instructions.
Bioanalysis of bile acid profiling and disposition assessments. The following analytes were extracted from previously frozen 24-well plates containing hepatocyte lysates and cell culture media (endogenous bile acid assessments only) utilized in bile acid profiling and disposition assessments: d8-TCA, TCA, CDCA, glycocholic acid, cholic acid, taurochenodeoxycholic acid, and glycochenodeoxycholic acid. Sample extraction and sample analysis was performed by LC/MS/MS as previously described (Jackson et al., 2016 ) using a TSQ Quantum Discovery MAX with an Ion Max ESI source (Thermo Electron).
Data analysis for evaluation of hepatobiliary disposition of bile acids. All calculations were performed using Microsoft Excel 2010 unless otherwise stated. Statistical analysis was performed using GraphPad Prism software version 6.0. All mass values from hepatobiliary disposition studies were normalized to the mean protein (mg) content per well. Total, cellular, and bile accumulations were determined as previously described (Jackson et al., 2016) . The biliary excretion index (BEI), biliary clearance, and intracellular concentrations of bile acids were calculated as previously described (Jackson et al., 2016) .
Cell culture for HepG2 cells. HepG2 cells were cultured and maintained in Eagle's Minimum Essential Medium (ATCC) containing 10% FBS (Gibco), 2 mM GlutaMax (Life Technologies), and penicillin-streptomycin (Life Technologies). Cells were seeded at a density of 400, 000 cells/well onto BioCoat Collagen Type I-Coated 24-well plates (BD), incubated for 20-24 h at 37 C and 5% CO 2 and then serum starved for 6 h in 0.3 ml/well of a serum free version of media described above. At the end of the 6 h, 0.3 ml of GGF2 vehicle control (0.1% GGF2 formulation buffer) or a 200 ng/ml solution of GGF2 or was added to achieve a final assay concentration of 100 ng/ml (2500 pM) GGF2. Cells were incubated with vehicle or GGF2 for 8-72 h. Fresh media with vehicle or GGF2 was applied every 24 h.
Cell culture for primary monkey hepatocytes. Cryopreserved primary cynomolgus hepatocytes (Corning, New York) were thawed, transferred into prewarmed Gentest CyroHepatocyte Recovery Medium (Corning), mixed by inversion and centrifuged at 100 Â g for 10 min at room temperature. Cells were resuspended in Gentest CyroHepatocyte Plating Medium (Corning) containing 10% FBS (Gibco, Gaithersburg, Maryland), and cell viability was determined based on hemocytometer counts of trypan blue-stained cells. Cells were seeded at a density of 400 000 cells/well onto BioCoat Collagen type ICoated 24-well plates (BD, Franklin Lakes, New Jersey) and gently tapped every 20-30 min for 2 h to create an evenly redistributed monolayer of cells. At 4 h following plating, media was replaced with 0.4 ml of serum-free Hepatocyte Culture Medium supplemented with EGF (Corning) and incubated overnight. The following day, medium was replaced with either 0.4 ml of GGF2 at 100 ng/ml (2500 pM) or GGF2 vehicle control (0.1% GGF2 formulation buffer). Cells were incubated with GGF2 or vehicle for 8-48 h. Fresh media with GGF2 or vehicle was applied every 24 h.
Gene expression analysis for HepG2 cells and primary monkey hepatocytes. Cells were processed for RNA isolation using RNAqueous-96 Total RNA Isolation Kit (Life Technologies) following manufacturer's instructions. cDNA was synthesized from 1 mg of RNA using the High Capacity cDNA Reverse Transcription Kit (Life Technologies) following the manufacturer's instructions.
Resulting cDNA was amplified using the TaqMan Gene Expression master mix and FAM-MGB probes and primers (Applied Biosystems).
Statistical analysis for HepG2 cells and primary monkey hepatocytes.
Statistical analyses for qPCR endpoints were performed using GraphPad Prism statistical software version 7.01. The Ct values of candidate genes for each sample were normalized to the Ct values of the housekeeping gene and used to calculate a FC over control with the 2 -DDCt method as previously described (Schmittgen and Livak, 2008) . Mean values of gene expression (FC) for 3 replicate experiments were compared with the corresponding vehicle-control for each time-point of exposure using a 2-way ANOVA. Comparisons between GGF2 and the vehicle control within a time point were performed using a Sidak's multiple comparison test. Liver biopsies were taken to evaluate histopathology in conjunction with the changes in liver-related serum chemistry parameters. At 3 days postdose, around the peak of the clinical chemistry response, there was no microscopic evidence of hepatocellular necrosis or apoptosis. Moderate to marked hyperplasia and hypertrophy of bile duct epithelium were the only histological changes observed (Supplementary Figure 1) . Both changes were observed in all animals treated with GGF2, including those that did not have liver chemistry changes, and these changes were not present in the biopsies obtained 2 weeks postdose (data not shown). GGF2 Suppresses CYP3A4 mRNA but Does Not Cause Cytotoxicity in Primary Human Hepatocytes Primary human hepatocytes in a sandwich-culture configuration were treated with GGF2 or control compounds for 6, 24, or 72 h of continuous exposure or 24 h of continuous exposure with a 48 h recovery. The concentrations of GGF2 used here were selected (using data available at the time of study initiation) to (1) bracket the expected plasma C max concentrations in humans based on early nonclinical data and (2) to replicate findings from prior CYP induction studies that had unexpectedly demonstrated suppression of CYP3A4 mRNA in primary human hepatocytes exposed to GGF2 for 24 h. The exposure data associated with the doses of GGF2 resulting in elevated serum liver chemistries became available after this study was initiated and reflected average plasma C max concentrations (11 450 pM at 1.5 mg/kg and 4680 pM at 0.378 mg/kg) 3.0-and 1.2-fold higher than the highest GGF2 concentration used in the present study (3760 pM). To confirm previous findings, cells were first assessed for changes in morphology, viability (LDH release), and CYP3A4 mRNA. GGF2 treatments did not alter cell morphology or induce cytotoxicity at any time point of exposure (data not shown). At 24 h, 3760 pM GGF2 reduced levels of CYP3A4 mRNA to as little as 8.4% of control and by 72 h this was further reduced to only 1.1% of control (Figure 3 ). However, after GGF2 was removed from the medium for 48 h, levels of CYP3A4 mRNA from the 24 h exposure wells returned to 74.4% of control (Figure 3 ).
RESULTS

Transient and Reversible Changes in Serum Bile
Targeted Analysis of Global Gene Expression Profiling Identifies Gene Expression Changes Affecting Bilirubin and Bile Acid Transport
Global gene expression profiling was performed to inform cellular mechanisms that could account for elevations in liver chemistries observed in the GGF2 clinical trials. Initially, targeted interrogation focused on the effect of 3760 pM GGF2 on candidate genes involved in bilirubin transport: UDP glucuronosyltransferase family 1 member a1 (UGT1A1), multidrug resistance-associated protein 2 (MRP2/ABCC2), breast cancer resistance protein 1 (BCRP1/ABCG2), multidrug resistanceassociated protein 3 (MRP3/ABCC3), and organic aniontransporting polypeptides 1B1 and 1B3 (OATP1B1-3/SLCO1B1-3) ( Figure 1A ). GGF2 reduced levels of OATP1B3 mRNA to 45% of control at 72 h ( Figure 4A ). No statistically significant changes were observed in the other candidate genes at any concentration or duration of GGF2.
A targeted interrogation was also performed for the effect of 3760 pM GGF2 on candidate genes involved in bile acid transport: MRP3, MRP4, sodium/taurocholate co-transporting polypeptide (NTCP/SLC10A1), bile salt export pump (BSEP/ ABCB11), bile acid coenzyme A: amino acid N-acyltransferase (BAAT) and fatty acid transport protein 5 (FATP5/SLC27A5/ BACS) ( Figure 1B ). GGF2 reduced levels of: MRP4 to 77% of control at 72 h; NTCP to 67% at 6 h, 58% at 24 h and 71% at 72 h; BSEP to 61% at 24 h; BAAT to 69% at 6 h, 52% at 24 h and 60% at 72 h; and FATP to 41% at 24 h and 44% at 72 h ( Figure 4B ). No other statistically significant changes were noted at any other concentration or duration. As previously noted, MRP2 and MRP3 were not significantly affected by any concentration or duration of GGF2 exposure.
Findings From Targeted Gene Expression Analysis Are Replicated in HepG2 and Primary Monkey Hepatocytes
To determine if candidate genes involved in bilirubin and bile acid transport were also affected in other hepatocyte models, HepG2 cells (human hepatoma cell line) and primary monkey hepatocytes were treated with GGF2 using a dosing regimen similar to the human hepatocyte experiments. FATP was not measured, but the effects on OATP1B3, MRP4, NTCP, BSEP, and BAAT were largely replicated in both the HepG2 cells and Cells were exposed to GGF2 formulation buffer or 3760 pM GGF2 for a total of 6, 24, or 72 h as well as 24 h with a 48 h washout. * indicates that multiple probe sets for this gene were analyzed; mean values are displayed on the graph. monkey hepatocytes (Supplementary Figure 2) . Additionally, GGF2 exposure decreased MRP2 to 66% at 24 h and 78% at 48 h; MRP3 to 69% at 24 h; and OATP1B1 to 53% at 24 h and 70% at 48 h in primary monkey hepatocytes (Supplementary Figure 2) . Statistically significant changes in these additional genes were not observed in HepG2 cells.
Pathway Enrichment Analysis of Global Gene Expression Profiling Identifies Transient and Reversible Changes in Xenobiotic
Metabolizing Enzymes and Acute Phase Response Genes Similar to IL-6 Microarray data were then analyzed to assess other mechanisms that could account for elevations in liver chemistries observed in the GGF2 clinical trials. Differential expression was determined by linear contrasts between each GGF2 concentration and the vehicle control at each time point of exposure (FDR p < .05 and jFCj > 2). A total of 952 probe sets were differentially expressed between GGF2 and vehicle with at least 1 concentration and duration of exposure. Hierarchical clustering of all significant probe sets demonstrates time-and GGF2 concentration-dependent responses, both up and down for these transcripts ( Figure 5 ). After a 48 h recovery period, probe sets for only 3 genes were differentially expressed at the highest concentration of 3760 pM GGF2: serpin peptidase inhibitor, clade A, member 1 (SERPINA1), olfactomedin-like 1 (OLFML1), and calcium channel, voltage-dependent, gamma subunit 8 (CACNG8).
Pathway enrichment analysis of genes that were differentially expressed between 3760 pM GGF2 and vehicle at each time point of exposure demonstrated temporally regulated transcriptional responses including GGF2-mediated induction of signaling cascades, suppression of xenobiotic metabolizing genes, and subsequent induction of acute phase response (APR) genes ( Figure 6 ). For example, "PXR/RXR Activation" is highly enriched among genes that are downregulated in response to GGF2 at 24 h ( Figure 6B ) reflecting the decrease in several drug metabolizing enzymes and transporters, including CYP3A4, while "Acute Phase Response Signaling" is highly enriched among genes that are upregulated in response to GGF2 at 72 h ( Figure 6A ) reflecting an increase in C-reactive protein and other immune signaling molecules. It was noted that many of the genes and pathways affected by GGF2 are similar to changes observed in primary human hepatocytes treated with IL-6 (Klein et al., 2015; Vee et al., 2009) . This included significant repression of CYP7A1, the rate limiting enzyme involved in bile acid biosynthesis. GGF2 at 3760 pM reduced levels of CYP7A1 to 8.9% at 6 h, 14% at 24 h and 16% at 72 h (Supplementary Figure 3) .
Transporter Studies Suggest GGF2 Inhibits Bile Acid Uptake and/or Accumulation Finally, because gene expression did not fully explain the clinical phenotype, investigation of transporter function was conducted to examine potential effects on bile acid homeostasis. Transporter Certified human hepatocytes in sandwich-culture configuration were treated in a similar manner as the gene expression study with GGF2 or control compounds for 6, 24, 48, or 72 h of continuous exposure or 24 h of continuous exposure with a 48 h recovery. Hepatobiliary disposition of endogenous bile acids as well as exogenous d8-TCA were evaluated using B-CLEAR technology with specific emphasis on 3 endpoints: (1) biliary clearance-movement of molecules from the medium into the bile pocket, (2) BEI-a measure of biliary efflux, describing movement of molecules from inside the hepatocyte to the bile pocket; and (3) total accumulation-hepatic uptake, describing molecules in the hepatocyte and the bile pocket.
GGF2 decreased total endogenous bile acid content of human hepatocytes to as low as 34% of control 48 h after exposure ( Figure 7A ). This decrease was comparable to positive control treatment with d5-CDCA, which decreased bile acid content to 22% compared with control ( Figure 7A ). Similar decreases in total endogenous bile acid content were also observed with IL-6 treatment ( Figure 7A ). The decrease in endogenous bile acid content was largely recovered to control levels following a 48 h washout of GGF2 ( Figure 7A ). This effect is consistent with transient and reversible suppression of CYP7A1 observed in the gene expression studies (Supplementary Figure 3) .
Biliary clearance of d8-TCA, a model bile acid, was decreased in a time-related manner following 6, 24, 48, and 72 h of GGF2 exposure in human hepatocytes ( Figure 7B ). The apparent decreases reached maximum (56.4% of control) after 72 h of treatment with 3760 pM GGF2; however, when compared with control, these decreases were not statistically significant. In contrast, biliary clearance of d8-TCA was reduced to 5.8% of control following treatment with a well-known inhibitor of bile acid transport, CsA ( Figure 7B ). IL-6 treatment also decreased biliary clearance of the model bile acid significantly in a timedependent manner reaching maximum effect (28.1% of control) after 72 h ( Figure 7B ). Following a 48 h wash out period, the apparent decreases in biliary clearance observed in response to GGF2 and CsA were mostly reversed ( Figure 7B ).
The BEI of d8-TCA was not affected by GGF2 treatment at any exposure time examined ( Figure 7C ). These results suggest that GGF2 treatment does not affect canalicular efflux (eg, BSEP) of bile acids. In contrast, biliary efflux of d8-TCA was reduced to 31.1% of control with 6 h of exposure to the well-established BSEP inhibitor CsA ( Figure 7C ). This inhibition was removed following a 48 h washout period ( Figure 7C ).
Significant decreases in the total accumulation d8-TCA were observed following GGF2, CsA, and IL-6 exposure ( Figure 7D ). These results suggested that all treatments reduced the uptake of d8-TCA into the hepatocytes. GGF2 treatment maximally reduced d8-TCA total accumulation to 51% of control following 72 h of 3760 pM GGF2 treatment ( Figure 7D ). CsA and IL-6 treatment reduced d8-TCA accumulation to 10% and 33.5% of control after 72 h of treatment ( Figure 7D ). The positive control, CsA, is well-known to inhibit uptake of bile acids consistent with these findings. Following a 48 h recovery period, d8-TCA accumulation was not significantly different from solvent control in SCHH treated with GGF2 or CsA, but remained significantly reduced in SCHH treated with IL-6 ( Figure 7D ).
DISCUSSION
Concomitant elevations in serum aminotransferases and bilirubin were replicated in monkeys administered a high dose of GGF2 and reflected, in part, the variability in sensitivity observed in the clinic. A critical finding here was that regardless of severity, all chemistries returned to baseline within 2 weeks postdose, indicating the transient and reversible nature of the liver response. Furthermore, no hepatocellular necrosis was observed histologically at either the peak of liver chemistry elevations or 2 weeks post-dose, thus serum bilirubin elevations could not be attributed to loss of viable hepatocyte mass. Interestingly, elevations in TBAs were also observed in all the monkeys treated with GGF2, and the monkey with the highest FC in serum bilirubin also had the highest increase in bile acids. Future efforts to analyze bile acids in clinical samples are needed to assess how observations in monkeys may translate to humans.
Elevated serum bile acids may provide some insight into the elevations in both serum aminotransferases and bilirubin. First, serum bile acid elevations may reflect GGF2-induced inhibition of apical bile acid transport which could result in toxic cellular bile acid accumulation. However, neither in vivo nor in vitro studies demonstrated any hepatocellular necrosis in response to GGF2, and examination of bile acid transport in sandwich cultured hepatocytes did not show an effect of GGF2 on biliary excretion. Rather, hepatocyte transporter studies indicated GGF2 decreased hepatocyte bile acid accumulation and biliary clearance by reducing bile acid uptake and endogenous bile acid biosynthesis. Additional support for these mechanisms is provided by the gene expression studies which showed significant GGF2-induced decreases in both CYP7A1 and NTCP mRNA. Therefore, the transporter studies account for elevated serum bile acid levels but do not support hepatocyte accumulation of bile acids as a mechanism underlying elevations in serum ALT. Decreased biliary clearance could result in decreased bile-acid dependent bile flow, which may contribute to elevations in total (and particularly conjugated) bilirubin. Although canalicular bile secretion can occur via independent transport systems, bile-acid dependent mechanisms have been estimated to account for 30%-60% of bile flow, depending on the species (Boyer, 2013; Esteller, 2008) . It is important to note that CYP7A1 deficiency alone does not result in hyperbilirubinemia (Pullinger et al., 2002) . However, the acute suppression of several factors influencing bile acid accumulation may result in a more significant impact on bile flow.
Another interesting finding in the monkey studies was GGF2-induced hyperplasia and hypertrophy of the biliary epithelium. These changes were observed in animals with and without elevated serum liver chemistries. Histological biliary changes were also noted in rats treated with GGF2, where no bilirubin or transaminase elevations were observed, even at very high doses. Therefore, the effects on the biliary epithelium in response to GGF2 in the animals may be unrelated to the biochemical abnormalities observed in the clinic. Biliary hypertrophy and hyperplasia are relatively common findings in preclinical animal studies that do not translate well to humans (Hailey et al., 2014) . In general, the mechanisms for these hypertrophic/hyperplastic responses are not completely understood and are often attributed to the high doses used in toxicology studies.
Doses 10-fold higher than human doses (3.2-fold species equivalent) were required to elicit serum chemistry changes similar to those observed in 2 patients at 1.5 and 0.38 mg/kg, suggesting monkeys are less sensitive to these effects than humans. Furthermore, at a more comparable dose that did not cause a liver response in monkeys (4.4 mg/kg, 0.95-fold species equivalent of 1.5 mg/kg), average plasma exposures were 3.3-fold higher than humans (9179 vs 2813 ngÁh/ml for AUC 24 ). Monkey and human GGF2 are 97.8% identical at the protein level and 100% identical within the EGF-like domain-the portion of full-length protein that is both necessary and sufficient for agonist regulation of the ErbB-receptor signaling. Therefore, it is unlikely the decrease in sensitivity is related to species differences in GGF2 specifically.
Gene expression profiling in human hepatocytes was used to provide additional insight into molecular mechanisms that may contribute to bilirubin elevations observed in the clinic. As in the monkey studies, no hepatocellular necrosis was observed in response to GGF2. However, GGF2-induced suppression of CYP3A4 mRNA and activity in primary human hepatocytes had been observed previously, and the mRNA effects were replicated in this study. Efforts are currently underway to evaluate the impact of this effect in vivo via clinical drug-drug interaction studies.
A substantial (approximately 45%) reduction was also observed in the mRNA levels of the bilirubin transporter OATP1B3 mRNA in response to GGF2. Loss of function polymorphisms in OATP1B1 and OATP1B3 occurring in Rotor syndrome have been shown to result in significant increases in both conjugated and unconjugated bilirubin (UCB) (Levitt and Levitt, 2014) . Given that Rotor syndrome results from polymorphisms in both genes, it is plausible that a 45% decrease in just OATP1B3 mRNA alone could, in part, account for the elevations in bilirubin observed in response to GGF2. Rotor syndrome is associated with higher elevations in conjugated bilirubin (16xULN) than were observed with GGF2 (12xULN). Furthermore, decreases in OATP1B3 mRNA could be important in combination with other factors and/or perhaps are more pronounced in certain sensitive individuals. Similarly sized (approximately 40%-60%) decreases were also observed in BAAT and FATP, enzymes that conjugate bile acids to glycine or taurine (Carlton et al., 2003; Hubbard et al., 2006) . Conjugation is important for biliary excretion of hydrophobic bile acids (Gerloff et al., 1998; Miyata et al., 2005) , and therefore decreased BAAT and FATP could reduce bile-acid dependent bile flow as described earlier.
The GGF2 effect on candidate bilirubin and bile acid transport genes were confirmed in HepG2 cells and primary monkey hepatocytes (as were the effects on CYP7A1 and 3A4 data not shown). Interestingly GGF2-induced decreases in MRP2, MRP3, and OATP1B1 mRNAs were also observed in primary monkey hepatocytes. Certainly, downregulation of these additional transporters would help to explain the elevations in serum bilirubin observed in both humans and monkeys. One possible explanation for why these specific changes were only observed in monkey hepatocytes is the use of a more sensitive hepatocyte donor. As noted earlier, significant inter-individual variability was observed in both the monkey and human studies, indicating that certain susceptibility factors may affect the response to GGF2.
Pathway enrichment analysis was also used to identify other factors that may explain the bilirubin response. At the 6 h time point, the strongest enrichment was observed among the PI3K-AKT, ERK-MAPK, and JAK-STAT signaling pathways. This is likely due to the pharmacological action of the drug, which targets ErbB receptors and has been shown to promote these and other signaling cascades in myocytes (Lim et al., 2015) . Signaling cascades were followed by enrichment of xenobiotic metabolizing pathways among down regulated genes at the 24 h time point and cytokine and APR signaling among up regulated genes at 72 h.
The pathway enrichment and the overall transcriptional profile observed in response to GGF2 is very similar to the transcriptional response to IL-6 (Klein et al., 2015; Vee et al., 2009) , suggesting that these molecules may operate via similar pathways and/or mechanisms. The proposed mechanisms responsible for down regulation of xenobiotic metabolizing genes in response to IL-6 is a shift in the translation of the transcription factor CCAAT/enhancer-binding protein b from an active isoform called liver-enriched activator protein to a dominant negative called liver-enriched inhibitory protein (LIP) (Jover et al., 2002; Mart ınez-Jiménez et al., 2005) . NRG-1 has been shown to promote an increase in LIP translation in MCF-7 cells (Park et al., 2013) .
Interestingly, IL-6 treatment is associated with downregulation of MPR2 in primary human hepatocytes (Klein et al., 2015; Vee et al., 2009) . As described earlier, perhaps with hepatocytes from sensitive donors, this effect may have also been observed in response to GGF2. However, other differences are also seen between IL-6 and GGF2 treatment. For example, IL-6 is associated with an increase in CYP2E1 (Klein et al., 2015) , whereas GGF2 treatment resulted in downregulation of this gene. This supports the conclusion that GGF2 likely acts through an ontarget effect (ie, through ErbB receptors) to induce these gene expression changes rather than indirectly via GGF2-mediated induction of IL-6. It is also important to note that there was no evidence in this study suggesting activation of stress response pathways and almost all gene expression changes returned to baseline with a 48-h washout, suggesting complete reversibility of the GGF2-induced transcriptional response.
In aggregate, the results of these translational experiments indicate that GGF2 does not cause significant hepatocellular necrosis, but likely transiently modifies hepatic handling of bilirubin and bile acids through an on-target effect. The decreased bile-acid dependent bile flow and reduction in the levels of bilirubin transporter mRNA may account for the elevations in serum bilirubin observed in the 2 clinical trial subjects. However, the data presented here do not provide an explanation for the elevations in serum aminotransferases associated with GGF2 treatment. Future work could help to explore the effects on bilirubin transporters at the protein level and the contribution of impaired transporter function and/or trafficking in response to GGF2.
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